Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression (Q87457254)
Jump to navigation
Jump to search
scientific article published on 02 March 2014
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression |
scientific article published on 02 March 2014 |
Statements
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression (English)
Noemi Reguart
Rafael Rosell
Felipe Cardenal
Andres F Cardona
Dolores Isla
Ramon Palmero
Teresa Moran
M Cinta Pallarès
Amelia Insa
Enric Carcereny
Margarita Majem
Cristina Queralt
Miguel A Molina